232 related articles for article (PubMed ID: 26130065)
1. Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury.
Heery CR; Singh BH; Rauckhorst M; Marté JL; Donahue RN; Grenga I; Rodell TC; Dahut W; Arlen PM; Madan RA; Schlom J; Gulley JL
Cancer Immunol Res; 2015 Nov; 3(11):1248-56. PubMed ID: 26130065
[TBL] [Abstract][Full Text] [Related]
2. Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine.
Hamilton DH; Litzinger MT; Jales A; Huang B; Fernando RI; Hodge JW; Ardiani A; Apelian D; Schlom J; Palena C
Oncotarget; 2013 Oct; 4(10):1777-90. PubMed ID: 24125763
[TBL] [Abstract][Full Text] [Related]
3. Randomized, Double-Blind, Placebo-Controlled Phase II Study of Yeast-Brachyury Vaccine (GI-6301) in Combination with Standard-of-Care Radiotherapy in Locally Advanced, Unresectable Chordoma.
DeMaria PJ; Bilusic M; Park DM; Heery CR; Donahue RN; Madan RA; Bagheri MH; Strauss J; Shen V; Marté JL; Steinberg SM; Schlom J; Gilbert MR; Gulley JL
Oncologist; 2021 May; 26(5):e847-e858. PubMed ID: 33594772
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC).
Bilusic M; McMahon S; Madan RA; Karzai F; Tsai YT; Donahue RN; Palena C; Jochems C; Marté JL; Floudas C; Strauss J; Redman J; Abdul Sater H; Rabizadeh S; Soon-Shiong P; Schlom J; Gulley JL
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33762322
[TBL] [Abstract][Full Text] [Related]
5. Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury.
Heery CR; Palena C; McMahon S; Donahue RN; Lepone LM; Grenga I; Dirmeier U; Cordes L; Marté J; Dahut W; Singh H; Madan RA; Fernando RI; Hamilton DH; Schlom J; Gulley JL
Clin Cancer Res; 2017 Nov; 23(22):6833-6845. PubMed ID: 28855356
[No Abstract] [Full Text] [Related]
6. Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer.
DeMaria PJ; Lee-Wisdom K; Donahue RN; Madan RA; Karzai F; Schwab A; Palena C; Jochems C; Floudas C; Strauss J; Marté JL; Redman JM; Dombi E; Widemann B; Korchin B; Adams T; Pico-Navarro C; Heery C; Schlom J; Gulley JL; Bilusic M
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34479925
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma.
Bilusic M; Heery CR; Arlen PM; Rauckhorst M; Apelian D; Tsang KY; Tucker JA; Jochems C; Schlom J; Gulley JL; Madan RA
Cancer Immunol Immunother; 2014 Mar; 63(3):225-34. PubMed ID: 24327292
[TBL] [Abstract][Full Text] [Related]
8. Brachyury, a vaccine target, is overexpressed in triple-negative breast cancer.
Hamilton DH; Roselli M; Ferroni P; Costarelli L; Cavaliere F; Taffuri M; Palena C; Guadagni F
Endocr Relat Cancer; 2016 Oct; 23(10):783-796. PubMed ID: 27580659
[TBL] [Abstract][Full Text] [Related]
9. Identification and characterization of a cytotoxic T-lymphocyte agonist epitope of brachyury, a transcription factor involved in epithelial to mesenchymal transition and metastasis.
Tucker JA; Jochems C; Boyerinas B; Fallon J; Greiner JW; Palena C; Rodell TC; Schlom J; Tsang KY
Cancer Immunol Immunother; 2014 Dec; 63(12):1307-17. PubMed ID: 25186612
[TBL] [Abstract][Full Text] [Related]
10. Nuclear Brachyury Expression Is Consistent in Chordoma, Common in Germ Cell Tumors and Small Cell Carcinomas, and Rare in Other Carcinomas and Sarcomas: An Immunohistochemical Study of 5229 Cases.
Miettinen M; Wang Z; Lasota J; Heery C; Schlom J; Palena C
Am J Surg Pathol; 2015 Oct; 39(10):1305-12. PubMed ID: 26099010
[TBL] [Abstract][Full Text] [Related]
11. A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)-Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer.
Gatti-Mays ME; Redman JM; Donahue RN; Palena C; Madan RA; Karzai F; Bilusic M; Sater HA; Marté JL; Cordes LM; McMahon S; Steinberg SM; Orpia A; Burmeister A; Schlom J; Gulley JL; Strauss J
Oncologist; 2020 Jun; 25(6):479-e899. PubMed ID: 31594913
[TBL] [Abstract][Full Text] [Related]
12. Cancer vaccines targeting the epithelial-mesenchymal transition: tissue distribution of brachyury and other drivers of the mesenchymal-like phenotype of carcinomas.
Hamilton DH; Litzinger MT; Fernando RI; Huang B; Palena C
Semin Oncol; 2012 Jun; 39(3):358-66. PubMed ID: 22595058
[TBL] [Abstract][Full Text] [Related]
13. Immune Targeting of Tumor Epithelial-Mesenchymal Transition via Brachyury-Based Vaccines.
Palena C; Hamilton DH
Adv Cancer Res; 2015; 128():69-93. PubMed ID: 26216630
[TBL] [Abstract][Full Text] [Related]
14. Development of Cancer Vaccines Targeting Brachyury, a Transcription Factor Associated with Tumor Epithelial-Mesenchymal Transition.
Hamilton DH; David JM; Dominguez C; Palena C
Cells Tissues Organs; 2017; 203(2):128-138. PubMed ID: 28214895
[TBL] [Abstract][Full Text] [Related]
15. Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients.
Snook AE; Baybutt TR; Xiang B; Abraham TS; Flickinger JC; Hyslop T; Zhan T; Kraft WK; Sato T; Waldman SA
J Immunother Cancer; 2019 Apr; 7(1):104. PubMed ID: 31010434
[TBL] [Abstract][Full Text] [Related]
16. Expression of epithelial-mesenchymal transition driver brachyury and status of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in predicting treatment responses to neoadjuvant chemotherapy of breast cancer.
Lee KH; Kim EY; Park YL; Do SI; Chae SW; Park CH
Tumour Biol; 2017 Jun; 39(6):1010428317710575. PubMed ID: 28621227
[TBL] [Abstract][Full Text] [Related]
17. The human T-box mesodermal transcription factor Brachyury is a candidate target for T-cell-mediated cancer immunotherapy.
Palena C; Polev DE; Tsang KY; Fernando RI; Litzinger M; Krukovskaya LL; Baranova AV; Kozlov AP; Schlom J
Clin Cancer Res; 2007 Apr; 13(8):2471-8. PubMed ID: 17438107
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients.
Conry RM; Curiel DT; Strong TV; Moore SE; Allen KO; Barlow DL; Shaw DR; LoBuglio AF
Clin Cancer Res; 2002 Sep; 8(9):2782-7. PubMed ID: 12231517
[TBL] [Abstract][Full Text] [Related]
19. Understanding Molecular Pathways and Targets of Brachyury in Epithelial-mesenchymal Transition (EMT) in Human Cancers.
Song W; Gobe GC
Curr Cancer Drug Targets; 2016; 16(7):586-93. PubMed ID: 27018266
[TBL] [Abstract][Full Text] [Related]
20. Phase I Trial of a Modified Vaccinia Ankara Priming Vaccine Followed by a Fowlpox Virus Boosting Vaccine Modified to Express Brachyury and Costimulatory Molecules in Advanced Solid Tumors.
Collins JM; Donahue RN; Tsai YT; Manu M; Palena C; Gatti-Mays ME; Marté JL; Madan RA; Karzai F; Heery CR; Strauss J; Abdul-Sater H; Cordes L; Schlom J; Gulley JL; Bilusic M
Oncologist; 2020 Jul; 25(7):560-e1006. PubMed ID: 31876334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
